PDCD1 and neoplasm: Marotte et al. [18] demonstrated the safety and superiority of a combination of adoptive transfer of PD-1-deficient T cells and targeted alpha therapy (TAT) targeting PD-L1 to control the growth of melanoma tumours in immunodeficient laboratory mice.